NCT00963534 - Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

lenalidomide, bendamustine, rituximab

"Phase I: Maximally tolerable dose of lenalidomide will be determined, starting with 5 mg per day, and up to maximally 25 mg per day. This treatment is given in combination with bendamustine and rituximab.~Phase II: Determination of progression free survival with treatment with lenalidomide (dosing determined in phase I) in combination with bendamustine and rituximab."

DRUG

lenalidomide, bendamustine, rituximab

lenalidomide: day 1-21, maximum 13 cycles bendamustine: days 1-2, cycle 1-6 rituximab: day1, cycle 1-6

Trial Locations (17)

Unknown

Århus University Hospital, Aarhus

Herlev Hospital, Copenhagen

Rigshospitalet, Department of Hematology, Copenhagen

Helsinki University Central Hospital, Helsinki

Haukeland University Hospital, Department of Oncology, Bergen

Norwegian Radium Hospital, Oslo

Ulleval University Hospital, Department of Oncology, Oslo

University Hospital of Stavanger, Department of Haematology and Oncology, Stavanger

University Hospital of Tromso, Department of Oncology, Tromsø

413 45

Sahlgrenska University Hospital, Department of Hematology, Gothenburg

581 85

University Hospital Linköping, Department of Hematology, Linköping

971 80

Sunderbyn Hospital, Department of Medicine, Luleå

221 85

University Hospital Lund, Department of Oncology, Lund

171 76

Karolinska University Hospital, Department of Hematology, Stockholm

851 86

Sundsvall Hospital, Department of Medicine, Sundsvall

981 85

University Hospital of Norrland, Department of Oncology, Umeå

751 85

Uppsala University Hospital, Department of Oncology, Uppsala